Michael Burry’s Top 5 Stock Picks


Today without a further ado, let’s check out what Insider Monkey tracked about Michael Burry’s top stock picks. NOW Inc. ranks fifth on the list. NOW Inc is engaged in downstream energy production and Burry started his position in the company in the fourth quarter of 2020 with buying $10.77 million of shares. Currently NOW shares show 4.79% of Scion Asset Management. The stock has rosen 50% since the beginning of 2021. According to Palm Valley Capital, NOW has 245 locations, and in June 2020 the company reported $269 million in cash without debts. The company also had $497 million of market cap. NOW Inc is followed by Lumen Technologies, Inc. on the fourth spot. As of the fourth quarter in 2020, Burry boosted his stake in Lumen technologies by 43%. The company is involved in facilities-based communications. Since the beginning of 2021 the company’s shares increased 24%, additionally Lumen offers over 8% of dividend yield to shareholders. According to Longleaf Partners, the company, earlier CenturyLink, was the winner of 2020, as International and Global had losses at around 5.8%; Enterprise revenues increased 0.8%, and Small and Medium Business decreased 5.8% due to coronavirus pandemic. Pfizer Inc. stands on the second spot. Burry invested in the company $31 million lately, now it means 13.83% of the overall portfolio. Interestingly, the company’s shares decreased dramatically in the beginning of 2021, despite it won a lot by developing the vaccine against the coronavirus. Pfizer closed the fourth quarter of 2020 with 11.8% growth in year-over-year revenue. Pfizer is headquartered in New York, and as of the fourth quarter of 2020, the company reported mixed results. At first, its earnings were $594 million, in other words – $0.10/share. In the same period in 2019, its earnings were $337 million or $0.06/share. Although the profit boosted 42 cents per share, it didn’t reach the projected 50 cents per share. Analysts predicted earlier the revenues would be around $11.48 billion, and the stock achieved better, as it jumped to $11.68 on a on a year-over-year basis. Reviewing the segments, we can see that revenues of the oncology shares went up by 17%, while rare disease vaccine revenues rocketed by 27%. Pfizer is projected to gain $15 billion in revenues due to its COVID-19 vaccine this year. For more interesting and useful information about Michael Burry’s top stock picks, please click and jump to the original article.